Trials / Completed
CompletedNCT00373373
Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML
A Double-blind, Placebo-controlled, Randomized, Multi-center Phase II Trial to Assess the Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- University Hospital Muenster · Academic / Other
- Sex
- All
- Age
- 61 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of the study is to determine, whether the addition of Sorafenib to standard chemotherapy in elderly patients with newly diagnosed AML improves treatment results (event free survival).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib | 2 x 400 mg/d |
| DRUG | Placebo | Chemotherapy + Placebo |
Timeline
- Start date
- 2006-09-01
- Primary completion
- 2009-07-01
- Completion
- 2009-07-01
- First posted
- 2006-09-08
- Last updated
- 2009-08-19
Locations
18 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT00373373. Inclusion in this directory is not an endorsement.